The use of 125I seed strands for intraluminal brachytherapy of malignant obstructive jaundice

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 5, 2012, Pages 317-323

  Chen, Yi ^a   Wang, Xiao Lin ^a   Yan, Zhi Ping ^a   Wang, Jian Hua ^a   Cheng, Jie Min ^a   Gong, Gao Quan ^a   Luo, Jian Jun ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

125I; brachytherapy; malignant obstructive jaundice

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; BILIRUBIN; IODINE 125; IRIDIUM;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILE DUCT CANCER; BILIRUBIN BLOOD LEVEL; BRACHYTHERAPY; CHOLANGITIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRANULOCYTE; HEMOBILIA; HUMAN; INFECTION; INTRALUMINAL BRACHYTHERAPY; MALE; MALIGNANT OBSTRUCTIVE JAUNDICE; OBSTRUCTIVE JAUNDICE; PRIORITY JOURNAL; STENT; THROMBOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METHODOLOGY; MIDDLE AGED; PALLIATIVE THERAPY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

BRACHYTHERAPY; FEMALE; HUMANS; IRIDIUM RADIOISOTOPES; JAUNDICE, OBSTRUCTIVE; MALE; MIDDLE AGED; PALLIATIVE CARE; PROSPECTIVE STUDIES; STENTS;

EID: 84862506879     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2011.0999     Document Type: Article

References (23)

1. Carrasco CH, Wallace S, Charnsangavej C. Expandable biliary endoprosthesis: An experimental study. AJR Am J Roentgenol 1985;145:1279.
2. Davids PH, Groen AK, Rauws EA, et al. Randomized trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 1992;340:1488.
3. Oikarinen H, Leinonen S, Karttunen A. Patency and complications of percutaneously inserted metallic stents in malignant biliary obstruction. J Vasc Interv Radiol 1999;10:1387.
4. Han YH, Kim MY, Kim SY, et al. Percutaneous insertion of Zilver stent in malignant biliary obstruction. Abdom Imaging 2006;31:433.
5. Yasumoto T, Yokoyama S, Nagaike K. Percutaneous transcholecystic metallic stent placement for malignant obstruction of the common bile duct: Preliminary clinical evaluation. J Vasc Interv Radiol 2010;21:252.
6. Kim HS, Lee DK, Kim HG, et al. Features of malignant biliary obstruction affecting the patency of metallic stents: A multicenter study. Gastrointest Endosc 2002;55:359.
7. Hareyama M, Sakata K, Oouchi A, et al. High-dose-rate versus low-dose-rate intracavitary therapy for carcinoma of the uterine cervix: A randomized trial. Cancer 2002;94:117.
8. Bruha R, Petrtyl J, Kubecova M, et al. Intraluminal brachytherapy and selfexpandable stents in nonresectable biliary malignancies - the question of long-term palliation. Hepatogastroenterology 2001;48:631.
9. Dvorak J, Jandik P, Melichar B, et al. Intraluminal high dose rate brachytherapy in the treatment of bile duct and gallbladder carcinomas. Hepatogastroenterology 2002;49:916.
10. Takahashi Y, Ito A, Sumida I, et al. Dosimetric consideration of individual 125I source strength measurement and a largescale comparison of that measured with a nominal value in permanent prostate implant brachytherapy. Radiat Med 2006;24:675.
11. Zhongmin W, Yu L, Fenju L, et al. Clinical efficacy of CT-guided iodine-125 seed implantation therapy in patients with advanced pancreatic cancer. Eur Radiol 2010;20:1786.
12. Trombetta MG, Colonias A, Makishi D, et al. Tolerance of the aorta using intraoperative iodine-125 interstitial brachytherapy in cancer of the lung. Brachytherapy 2008;7:50.
13. Guo JH, Teng GJ, Zhu GY, et al. Self-expandable esophageal stent loaded with 125I seeds: Initial experience in patients with advanced esophageal cancer. Radiology 2008;247:574.
14. Mutignani M, Shah SK, Morganti AG, et al. Treatment of unresectable pancreatic carcinoma by intraluminal brachytherapy in the duct of Wirsung. Endoscopy 2002;34:555.
15. Hatzidakis A, Krokidis M, Kalbakis K, et al. ePTFE/FEP-covered metallic stents for palliation of malignant biliary disease: Can tumor ingrowth be prevented? Cardiovasc Intervent Radiol 2007;30:950.
16. Yoon WJ, Lee JK, Lee KH, et al. A comparison of covered and uncovered Wallstents for the management of distal malignant biliary obstruction. Gastrointest Endosc 2006;63: 996.
17. Chen Y, Wang XL, Yan ZP, et al. HDR-192Ir intraluminal brachytherapy in treatment of malignant obstructive jaundice. World J Gastroenterol 2004;10:3506.
18. Chargari C, Magné N, Dumas I, et al. Physics contributions and clinical outcome with 3D-MRI-based pulsed-dose-rate intracavitary brachytherapy in cervical cancer patients. Int J Radiat Oncol Biol Phys 2009;74:133.
19. Sur RK, Levin CV, Donde B, et al. Prospective randomized trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma - an International Atomic Energy Agency study. Int J Radiat Oncol Biol Phys 2002;53:127.
20. Doyle LA, Harrison AS, Cognetti D, et al. Reirradiation of head and neck cancer with high-dose-rate brachytherapy: A customizable intraluminal solution for postoperative treatment of tracheal mucosa recurrence. Brachytherapy 2010;10:154.
21. Corner C, Bryant L, Chapman C, et al. High-dose-rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma. Brachytherapy 2010;9:66.
22. Liu Y, Lu Z, Zou DW, et al. Intraluminal implantation of radioactive stents for treatment of primary carcinomas of the peripancreatic-head region: A pilot study. Gastrointest Endosc 2009;69:1067.
23. Li SY, Kim CW, Jeon UB, et al. Early infectious complications of percutaneous metallic stent insertion for malignant biliary obstruction. AJR Am J Roentgenol 2010;194:261.